Neuro-Oncology News

The FDA granted orphan drug designation to iniparib for treatment of malignant glioma, according to the agent’s manufacturer.

Patients with glioma who completed the 8-week GLioma Atkins-based Diet experienced “meaningful” ketonuria and significant systemic and cerebral metabolic changes, according to results from a small study published in Neurology.

A survey of community neurologists demonstrated four primary themes associated with the impact of the COVID-19 pandemic in this group, specifically highlighting “the unusual environment” in which these providers practice.

Chimeric antigen receptor T cells have emerged “as a promising therapeutic avenue” for the treatment of glioblastoma, though various factors still limit its efficacy, according to a review published in Neurology.

Dabrafenib plus trametinib exhibited encouraging activity among patients with recurrent or refractory BRAF V600E mutation-positive glioma, according to study results.

Morning administration of temozolomide appeared associated with longer OS compared with evening administration among patients with newly diagnosed glioblastoma, according to study results published in Neuro-Oncology Advances.

The FDA granted orphan drug designation to CYNK-001 for the treatment of malignant gliomas, according to the agent’s manufacturer.

Nearly 20% of pediatric brain tumors occur in the pituitary region, and more than two-thirds of pituitary region tumors were present in girls, according to study findings published in Pituitary.

Toxoplasma gondii infection appeared to increase the risk for glioma in adults, according to study results published in International Journal of Cancer.

A personalized cancer vaccine improved PFS compared with historical outcomes with standard-of-care treatment for patients with newly diagnosed glioblastoma, according to phase 2 study results.